Kvalvik, Liv Grimstvedt http://orcid.org/0000-0001-6520-9057
Klungsøyr, Kari http://orcid.org/0000-0003-2482-1690
Igland, Jannicke http://orcid.org/0000-0002-2289-0978
Caspersen, Ida Henriette http://orcid.org/0000-0003-2591-8435
Brantsæter, Anne Lise http://orcid.org/0000-0001-6315-7134
Solberg, Berit Skretting http://orcid.org/0000-0002-0168-1675
Hartman, Catharina http://orcid.org/0000-0002-8094-8859
Schweren, Lizanne Johanna Stephanie http://orcid.org/0000-0001-6018-5316
Larsson, Henrik http://orcid.org/0000-0002-6851-3297
Li, Lin http://orcid.org/0000-0002-7946-4574
Forthun, Ingeborg http://orcid.org/0000-0001-8097-6959
Johansson, Stefan http://orcid.org/0000-0002-2298-7008
Arias Vasquez, Alejandro http://orcid.org/0000-0002-4786-0169
Haavik, Jan http://orcid.org/0000-0001-7865-2808
Funding for this research was provided by:
Horizon 2020 (728018)
University of Bergen
Article History
Received: 26 April 2021
Accepted: 4 January 2022
First Online: 23 January 2022
Declarations
:
: During the past 3 years, Jan Haavik has received lecture honoraria as part of continuing medical education programs sponsored by Shire, Takeda, Medice and Biocodex. Henrik Larsson has served as a speaker for Evolan Pharma and Shire/Takeda and has received research grants from Shire/Takeda; all outside the submitted work. The other authors declare no conflict of interest.
: The establishment of MoBa and initial data collection was based on a license from the Norwegian Data protection agency and approval from The Regional Committee for Medical Research Ethics. The MoBa cohort is currently regulated by the Norwegian Health Registry Act. The current study was approved by The Regional Committee for Medical Research Ethics (2015/2055).